Athersys To Present At 13th Annual BIO CEO & Investor Conference
CLEVELAND, Feb. 8, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Company is scheduled to present at the 13th Annual BIO CEO & Investor Conference, being held February 14 and 15, 2011, at the Waldorf-Astoria Hotel in New York City.
Gil Van Bokkelen, Ph.D., Chairman and Chief Executive Officer, will provide a corporate and product development overview of the Company on Monday, February 14, 2011 at 3:30 pm EST. Investors may listen to a live audio web cast of Athersys' presentation by accessing the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2011/19113487.cfm . A web cast replay of the presentation can be accessed via the Company's web site at www.athersys.com, under the "Investors Section."
About AthersysAthersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem ®, a patented, adult-derived "off-the-shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE ®). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products. More information is available at www.athersys.com . The Athersys logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548 .
CONTACT: William (B.J.) Lehmann, J.D. President and COO Tel: (216) 431-9900 email@example.com Investor Relations: Lisa M. Wilson In-Site Communications Tel: (917) 543-9932 firstname.lastname@example.org
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV